Consensus bluebird bio, Inc.

Equities

BLUE

US09609G1004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.9125 ^USD	-1.13%		-4.25%	-33.88%

Mar. 27	Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating	MT
Mar. 27	Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating	MT

Evolution of the average Target Price on bluebird bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fa0c50e252040e423f9356b257e.-uiF0UhTO5z_Q1wTktF95Uq7zibazNn9vPdVq_b3C40.v9zigjtia8mpcBZD2aklqhDu_lGptOm6-cADnZOvTLiisbC8DGZ36psHMw~5c89a7e0332eb2ef455560359323042c

Analyst Recommendations on bluebird bio, Inc.

Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating	Mar. 27	MT
Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating	Mar. 27	MT
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating	Mar. 26	MT
Wedbush Adjusts bluebird bio's Price Target to $1.68 From $3, Maintains Neutral Rating	Mar. 19	MT
HSBC Adjusts bluebird bio's Price Target to $1.02 From $2.31, Keeps Reduce Rating	Mar. 05	MT
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
Wells Fargo Adjusts Bluebird Bio Price Target to $5 From $8, Maintains Equal Weight Rating	Dec. 15	MT
Baird Adjusts Price Target on bluebird bio to $7 From $10, Maintains Outperform Rating	Dec. 12	MT
BofA Securities Adjusts Price Target on bluebird bio to $12 From $11, Maintains Buy Rating	Dec. 11	MT
Wedbush Lowers bluebird bio's PT to $3 From $5, Says Black Box Warning for Lyfgenia Makes it Difficult to Justify Premium; Maintains Neutral Rating	Dec. 11	MT
Top Stories at Midday: Unemployment Rate Falls; Carrier Global Rises on Honeywell Deal; Tesla's Norway Labor Woes; FDA Approves Casgevy, Lyfgenia; Putin's 2024 Presidential Run	Dec. 08	MT
Morgan Stanley Upgrades Bluebird Bio to Equalweight From Underweight, Boosts Price Target to $7 From $3	Dec. 08	MT
Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating	Nov. 08	MT
Cantor Fitzgerald Initiates Coverage on bluebird bio with Neutral Rating	23-10-17	MT
HSBC Initiates bluebird bio With Buy Rating, Price Target is $4.21	23-09-06	MT
BofA Securities Upgrades bluebird bio to Buy From Neutral on Gene Therapy Potential, Adjusts Price Target to $10 From $6	23-07-19	MT
BofA Securities Upgrades bluebird bio to Buy From Neutral, Adjusts Price Target to $10 From $6	23-07-19	MT
RBC Trims bluebird bio's Price Target to $6 From $8, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Barclays Upgrades bluebird bio to Overweight From Equalweight, Adjusts Price Target to $8 From $7	23-06-01	MT
Wedbush Adjusts bluebird bio Price Target to $7 From $5, Maintains Neutral Rating	23-05-09	MT
Morgan Stanley Trims Price Target on bluebird bio to $3 From $4, Maintains Underweight Rating	23-04-03	MT
BofA Securities Adjusts Price Target on bluebird bio to $6 From $8, Maintains Neutral Rating	23-03-30	MT
Wedbush Lowers bluebird bio's Price Target to $5 From $9, Neutral Rating Kept	23-03-29	MT
Baird Starts bluebird bio at Outperform With $10 Price Target	23-03-07	MT
Morgan Stanley Adjusts Price Target on Bluebird Bio to $4 From $3, Maintains Underweight Rating	23-01-24	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.9125 USD

Average target price

4.062 USD

Spread / Average Target

+345.11%

High Price Target

8 USD

Spread / Highest target

+776.71%

Low Price Target

1 USD

Spread / Lowest Target

+9.59%

Consensus detail

Consensus revision (last 18 months)

Analysts covering bluebird bio, Inc.

Wells Fargo Securities
Wedbush
HSBC
Baird
BofA Securities
Morgan Stanley
Cantor Fitzgerald
RBC Capital Markets
Barclays
SVB Securities LLC
Raymond James
Goldman Sachs
SVB Leerink
Cowen
Berenberg Bank
Mizuho Securities
Canaccord Genuity
JPMorgan Chase
Piper Sandler
BMO Capital
Jefferies & Co.
Stifel Nicolaus
J.P. Morgan Chase
William Blair & Co.

Ratings for bluebird bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar